ProMetic Life Sciences Inc.

Description

Mr. Paul Mesburis is a Chartered Accountant and Chartered Financial Analyst, with more than twenty years of experience in financial and capital markets. His capital markets experience encompasses roles for both buy-side and sell-side firms. On the buy-side, his previous roles have included senior portfolio manager roles for both global and domestic equity mutual funds at Canadian financial services companies (private and publicly-listed) and for a mezzanine debt/private equity fund at a publicly-listed Canadian bank.

Mr. Pierre Laurin is a seasoned senior executive with more than 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic's platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As CEO of the Company since its inception and Chairman unti March 2011, he took the company public on the Toronto Stock Exchange and has since raised over $450 million through equity financings and multinational funding. Mr.

Mr. Wendel served as Vice Chairman and Chief Executive Officer of Abraxis BioScience until October 15, 2010, when Abraxis was acquired by Celgene Corporation. He formerly held the positions of Executive Vice-President of Corporate Development of Abraxis BioScience. Mr. Wendel joined American Pharmaceutical Partners (“APP”) in 2004 as Vice-President of Corporate Development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development.

Company contacts

Products & services

Similar companies nearby